Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion

Executive Summary

Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary endpoint and could provide a boost for Finland's multinational and now pure-play pharma company, Orion, plus Bayer too.

 

Advertisement

Related Content

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Q4 Preview: How Will Bayer Survive Patent Cliff?
J&J’s Erleada Gives Chase To Xtandi For Non-Metastatic Prostate Cancer With Approval In Europe
Bayer Still Confident Of Future Prospects Post-Xarelto
Bayer Eyes More Link-Ups Like Loxo After Pipeline Blips
Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer
Q3 Pharma Earnings Preview: Novo Nordisk, Shire And Teva
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Bayer signs €50m deal for Orion's prostate cancer drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124050

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel